There was a mention, I believe made by Rabin, I believe, that within a year, the commercial prospects, i.e. revenue for ACTC, will compare to and surpass Lipitor.
Also, I believe Rabin made it pretty clear there are no immediate plans to announce a jv with a large pharma and that ACTC is fully capable and will proceed for awhile on it's own.
My sense is they are looking for a dramatic price increase following the october release, and a major release on the hemangioblast patent and it's dramatic revenue potential and defiitely amove to a better board, all of which have the potential, I stress potential, to negate the need for a rs, imo.
Market Data 
Markets 
AI
